This

Current Report on Form 8-K (including information included or incorporated by

reference herein) includes "forward-looking statements" within the meaning of

the safe harbor provisions of the United States Private Securities Litigation

Reform Act of 1995. Such statements may include, but are not limited to,

statements about the benefits of the pending merger between Pfizer and Wyeth,

including future financial and operating results, the combined company's plans,

objectives, expectations and intentions and other statements that are not

historical facts. Such statements are based upon the current beliefs and

expectations of Pfizer's and Wyeth's management and are subject to significant

risks and uncertainties. Actual results may differ from those set forth in the

forward-looking statements. Neither Pfizer nor Wyeth undertake any obligation to

update publicly or revise any forward-looking statements. The

following factors, among others, could cause actual results to differ from those

set forth in the forward-looking statements: the possibility that the expected

synergies from the pending merger of Pfizer and Wyeth will not be realized, or

will not be realized within the expected time period, due to, among other

things, the impact of pharmaceutical industry regulation and pending legislation

that could affect the pharmaceutical industry; the risk that the businesses will

not be integrated successfully; disruption from the merger making it more

difficult to maintain business and operational relationships; the possibility

that the merger does not close, including, but not limited to, due to the

failure to satisfy the closing conditions; Pfizer's and Wyeth's ability to

accurately predict future market conditions; dependence on the effectiveness of

Pfizer's and Wyeth's patents and other protections for innovative products; the

risk of new and changing regulation and health policies in the U.S. and

internationally and the exposure to litigation and/or regulatory actions.

Additional factors that could cause results to differ materially from those

described in the forward-looking statements can be found in Pfizer's 2008 Annual

Report on Form 10-K filed with the Securities and Exchange Commission (the

"SEC") on February 27, 2009, Wyeth's 2008 Annual Report on Form 10-K filed with

the SEC on February 27, 2009, as amended on April 30, 2009, and Pfizer s

Registration Statement on Form S-4, which was declared effective by the SEC on

June 17, 2009, included in the Risk Factors section of each of these filings,

and each company's other filings with the SEC available at the SEC's Internet

site (http://www.sec.gov).

Additional

Information

In

connection with the pending acquisition of Wyeth, Pfizer has filed with the SEC,

and the SEC has declared effective, a Registration Statement on Form S-4 that

includes a proxy statement of Wyeth that also constitutes a prospectus of

Pfizer. Wyeth mailed the proxy statement/prospectus to its stockholders, who

approved the pending acquisition on July 20, 2009. Pfizer urges investors and

security holders to read the proxy statement/prospectus regarding the pending

acquisition because it contains important information. You may obtain copies of

all documents filed with the SEC regarding this transaction, free of charge, at

the SEC s website (www.sec.gov). You may also obtain these documents, free of

charge, from Pfizer s website, www.pfizer.com, under the tab Investors and

then under the tab SEC Filings. You may also obtain these documents, free of

charge, from Wyeth s website, www.wyeth.com, under the heading Investor

Relations and then under the tab Financial Reports/SEC Filings. Information

regarding the persons who may, under the rules of the SEC, be deemed to have

been participants in the solicitation of the Wyeth stockholders in connection

with the pending acquisition is set forth in the proxy statement/prospectus. You

can find information about Pfizer s executive officers and directors in its

definitive proxy statement filed with the SEC on March 13, 2009. You can find

information about Wyeth s executive officers and directors in its Annual Report

on Form 10-K for the fiscal year ended December 31, 2008, as amended by Wyeth s

Annual Report on Form 10-K/A, filed with the SEC on February 27, 2009 and April

30, 2009, respectively, and the definitive proxy statement/prospectus for

Wyeth s 2009 Annual Meeting of Shareholders, which was filed with the SEC on

June 17, 2009. The information contained in Pfizer s and Wyeth s websites is not

incorporated by reference and does not constitute a part of this Current Report

on Form 8-K.

Item

9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Unaudited Pro Forma

Condensed Combined Financial Statements of Pfizer and Wyeth as of and for

the six months ended June 28, 2009 and for the year ended December 31,

2008.

99.2

Wyeth s Unaudited

Historical Consolidated Condensed Financial Statements as of and for the

six months ended June 30, 2009 and notes

thereto.

SIGNATURE

Under the

requirements of the Securities Exchange Act of 1934, the registrant has caused

this report to be signed on its behalf by the authorized

undersigned.

PFIZER

INC.

By:

/s/ Matthew

Lepore

Matthew

Lepore

Vice

President, Chief Counsel Corporate Governance,

and

Assistant General Counsel

Dated:

October 14, 2009

EXHIBIT

INDEX

Exhibit

No.

Description

99.1

Unaudited Pro Forma

Condensed Combined Financial Statements of Pfizer and Wyeth as of and for

the six months ended June 28, 2009 and for the year ended December 31,

2008.

99.2

Wyeth s Unaudited

Historical Consolidated Condensed Financial Statements as of and for the

six months ended June 30, 2009 and notes

thereto.